Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib
11 septembra, 2020 7:52 pmProgram: Oral and Poster Abstracts Type: Oral Session: 634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies ...
Results of PAC203: A Randomized Phase II Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
11 septembra, 2020 7:52 pmProgram: Oral and Poster Abstracts Type: Oral Session: 634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies ...
Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study
11 septembra, 2020 7:52 pmProgram: Oral and Poster Abstracts Type: Oral Session: 634. Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies ...
Myeloproliferativní neoplazie – zajímavá sdělení z ASH®
11 septembra, 2020 7:52 pmV rámci každoročního kongresu Americké hematologické společnosti, jenž se konal ve dnech 7.–10. prosince 2019 v Orlandu na Floridě (Spojené státy americké) bylo prezentováno...
Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase II Superiority Trial
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II Hematology Disease Topics &...
Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I Hematology Disease Topics & Pathways: Diseases,...
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase Ib Results
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 637. Myelodysplastic Syndromes – Clinical Studies: Combination Therapies Hematology...
Myelodysplastický syndrom – co přinesl ASH® 2019
11 septembra, 2020 7:51 pmNa prvém místě jmenuji dvě velmi důležité práce týkající se přesnější stratifikace nemocných a stanovení prognózy. U myelodysplastického syndromu (MDS) nalezneme minimálně jednu...
A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children
11 septembra, 2020 7:51 pmProgram Oral and Poster Abstracts Session 311. Disorders of Platelet Number or Function: Poster II Hematology Disease Topics...
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 311. Disorders of Platelet Number or Function: Advances in ITP...